Opportunity
Deep brain stimulation (DBS) is a widely used treatment for neurodegenerative disorders like Parkinson’s disease (PD) and epilepsy, targeting motor symptoms such as tremors, rigidity, and slowed movement. However, conventional open-loop DBS systems deliver continuous electrical stimulation regardless of the patient’s physiological state, leading to significant drawbacks. These include adverse side effects from excessive current flow to adjacent brain structures, reduced battery life of implantable devices, and the need for frequent replacement surgeries. The lack of adaptive stimulation also means the therapy is not optimized for dynamic changes in neural activity, potentially compromising efficacy and patient comfort. This patent addresses these limitations by introducing a closed-loop DBS system that dynamically adjusts stimulation based on real-time detection of abnormal neural oscillations, specifically in the beta band (13–40 Hz), which is linked to PD symptoms.
Technology
The patent discloses a closed-loop DBS system comprising neural electrodes implanted in deep brain nuclei (e.g., putamen, subthalamic nucleus, or globus pallidus internus) to record local field potential (LFP) signals. A key innovation is the integration of a real-time processing unit (e.g., an FPGA or ASIC) that analyzes LFP data to detect abnormal beta oscillations. Upon detection, the system triggers targeted DBS pulses only when needed, avoiding continuous stimulation. The technology leverages:
1. Beta-band oscillation detection: The system calculates averaged LFP power in the beta band (13–40 Hz) and compares it to a healthy baseline. Abnormal oscillations trigger stimulation.
2. Adaptive stimulation: DBS pulses (e.g., 130 Hz frequency, 100 μA current) are delivered in response to pathological signals, reducing total stimulation time by 55–69% compared to open-loop systems.
3. Efficient data handling: LFP data is packaged via UDP protocols and processed using sliding-window methods for real-time analysis.
This approach ensures precise, demand-driven therapy while minimizing side effects and energy consumption.
Advantages
- Reduced stimulation time: Cuts total stimulation by 55.4% (rotenone-induced PD models) and 69.3% (6-OHDA-induced PD models).
- Minimized side effects: Avoids overstimulation of non-target brain regions.
- Battery efficiency: Extends device lifespan by reducing unnecessary pulses.
- Improved efficacy: Restores motor function to near-normal levels in preclinical models.
Applications
- Parkinson’s disease: Regulates tremors, rigidity, and bradykinesia.
- Epilepsy: Potential for seizure suppression via adaptive stimulation.
- Other movement disorders: Applicable to dystonia or essential tremor.
- Research tools: Enables study of neural oscillations in neurodegenerative diseases.
